Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002756 · ClinicalTrials.gov registry record · Phase 2
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
A Phase 2 study of Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
- 20
- Study locations
NCT00002756 is a Phase 2 study of Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 221 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00002756, a Phase 2 study of Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them as induction intensification may kill more cancer cells. PURPOSE: This phase II trial is studying how well induction intensification works in treating infants with newly diagnosed acute lymphocytic leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- Southern California Permanente Medical Group - Downey
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital - Long Beach
- Children's Hospital Central California - Madera
- Children's Hospital and Research Center - Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Sutter Cancer Center - Sacramento
- Kaiser Permanente Medical Center - Oakland - Sacramento
- Children's Hospital and Health Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Santa Barbara Cottage Children's Hospital - Santa Barbara
- Stanford Cancer Center at Stanford University Medical Center - Stanford
Connecticut
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center - Farmington
- Yale Cancer Center - New Haven
Florida
- Broward General Medical Center Cancer Center - Fort Lauderdale
- Lee Cancer Care of Lee Memorial Health System - Fort Myers
Alabama
- Comprehensive Cancer Center at University of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 1996-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002756
The ClinicalTrials.gov registry entry for NCT00002756 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (55% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002756 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00002756 about?
NCT00002756 is a clinical study titled "Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them as induction intensification may kill more cancer cells. PURPOSE: This phase II trial is studying how well induction...
What is the current status of trial NCT00002756?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 1996-06. Estimated completion is 2012-03.
What conditions does trial NCT00002756 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00002756?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002756?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002756 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.